Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Descripció completa

Dades bibliogràfiques
Autors principals: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Format: Article
Idioma:English
Publicat: Elsevier 2023-08-01
Col·lecció:Journal of Allergy and Clinical Immunology: Global
Matèries:
Accés en línia:http://www.sciencedirect.com/science/article/pii/S277282932300053X